Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Victoria, Wirtz"'
Autor:
Arun Naini, Max Peter Bartetzko, Someswara Rao Sanapala, Felix Broecker, Victoria Wirtz, Marilda P. Lisboa, Sharavathi G. Parameswarappa, Daniel Knopp, Jessica Przygodda, Matthias Hakelberg, Rosalind Pan, Axay Patel, Laurent Chorro, Arthur Illenberger, Christopher Ponce, Srinivas Kodali, Jacqueline Lypowy, Annaliesa S. Anderson, Robert G. K. Donald, Arne von Bonin, Claney L. Pereira
Publikováno v:
JACS Au. 2:2135-2151
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a38b04fabf01cd54cb00ae2e8b8595ce
https://doi.org/10.1021/jacsau.2c00401
https://doi.org/10.1021/jacsau.2c00401
Autor:
Michele Potashman, Lila Brady, Susan Durham, Victoria Wirtz, Gilbert L’Italien, Vladimir Coric, Günter Höglinger, Horacio Kaufmann, Phillip Low, Nikolaus McFarland, Wassilios Meissner, Patricio Millar Vernetti, Huw Morris, Werner Poewe, Klaus Seppi, Wolfgang Singer, Steven Vernino, Irfan Qureshi
Publikováno v:
Wednesday, April 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::159602f4d64b5ecdfa4661c8fd351bf4
https://doi.org/10.1212/wnl.0000000000202223
https://doi.org/10.1212/wnl.0000000000202223
Autor:
Michele Potashman, Isabella Huang, Susan Durham, Victoria Wirtz, Gilbert L’Italien, Vladimir Coric, Andrea De Palma, Triza Brion, Günter Höglinger, Horacio Kaufmann, Phillip Low, Nikolaus McFarland, Wassilios Meissner, Patricio Millar Vernetti, Huw Morris, Werner Poewe, Klaus Seppi, Wolfgang Singer, Steven Vernino, Irfan Qureshi
Publikováno v:
Tuesday, April 25.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8999efe0dc23689c2d3401097276d68
https://doi.org/10.1212/wnl.0000000000202288
https://doi.org/10.1212/wnl.0000000000202288
Autor:
Robert M. Berman, Sonja Hartmann, Victoria Wirtz, Richard Larouche, Irfan Qureshi, Matt S. Anderson, Meghan Lovegren, Vlad Coric, Mario Tanguay
Publikováno v:
Clinical Pharmacology in Drug Development. 9:476-485
Orally administered riluzole extends survival in patients with amyotrophic lateral sclerosis, although it has significant shortcomings (eg, adverse events, dysphagic patients) that limit its utility. BHV-0223 is a Zydis-based orally disintegrating fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::997c410413990e836b9a5e863c186db4
https://doi.org/10.1002/cpdd.747
https://doi.org/10.1002/cpdd.747
Autor:
Max Lataillade, Jennifer Chiarella, Rong Yang, Steven Schnittman, Victoria Wirtz, Jonathan Uy, Daniel Seekins, Mark Krystal, Marco Mancini, Donnie McGrath, Birgitte Simen, Michael Egholm, Michael Kozal
Publikováno v:
PLoS ONE, Vol 5, Iss 6, p e10952 (2010)
CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with tenofovir-emtricitabine in ARV-naïve subjects from 5 continents.Determine the baseline rate and clinical significance of TDR mutations using ultr
Externí odkaz:
https://doaj.org/article/8375a24f827a4f72b10609d3e67974e1
Publikováno v:
QJM: An International Journal of Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13780668764402221bd9703550285fca
https://doi.org/10.1093/qjmed/hcw123.002
https://doi.org/10.1093/qjmed/hcw123.002
Autor:
Michael J, Kozal, Sergio, Lupo, Edwin, DeJesus, Jean-Michel, Molina, Cheryl, McDonald, Francois, Raffi, Jorge, Benetucci, Marco, Mancini, Rong, Yang, Victoria, Wirtz, Lisa, Percival, Jenny, Zhang, Li, Zhu, Dilek, Arikan, Awny, Farajallah, Bach-Yen, Nguyen, Randi, Leavitt, Donnie, McGrath, Max, Lataillade, The Spartan Study Team
Publikováno v:
HIV Clinical Trials. 13:119-130
Nucleoside and ritonavir (RTV) toxicities have led to increased interest in nucleoside reverse transcriptase inhibitors (NRTIs) and RTV-sparing antiretroviral regimens. SPARTAN was a multicenter, randomized, open-label, noncomparative pilot study eva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dc119fbf98dd8324271c149f6a32a68
https://doi.org/10.1310/hct1303-119
https://doi.org/10.1310/hct1303-119
Publikováno v:
Clinical Infectious Diseases. 48:1323-1326
This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a16c6bdd7da4f28b604be41bd01abd7
https://doi.org/10.1086/597776
https://doi.org/10.1086/597776
Autor:
Monique Van den Dungen, Claudia Gruber, Emilio Ledesma, Francisco Antunes, Linda Odeshoo, Adriano Lazzarin, Clifford Leen, Eric Van Wijngaerden, Andrzej Horban, Victoria Wirtz, Dominique Salmon Ceron, José M. Gatell
Publikováno v:
Clinical Infectious Diseases. 44:1484-1492
BACKGROUND Atazanavir is a once-daily protease inhibitor (PI) for the treatment of human immunodeficiency virus (HIV) infection that has previously been studied in cohorts of treatment-naive and treatment-experienced patients. Limited data are availa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::830d4bd4d4a5c4299b594ec4891623a4
https://doi.org/10.1086/517497
https://doi.org/10.1086/517497
Autor:
Wenhua Hu, Awny Farajallah, David Butcher, Cheryl McDonald, Salomé N. Juethner, Jonathan Uy, Victoria Wirtz, Donnie McGrath, Graeme Moyle
Publikováno v:
AIDS patient care and STDs. 26(5)
CASTLE was a randomized 96-week study that demonstrated that atazanavir/ritonavir (ATV/r) was noninferior to lopinavir/ritonavir (LPV/r) in treatment-naive HIV-infected patients. Analyses were carried out among patients who received ATV/r in the CAST
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c218f5591b20420c6e31289cd0a11357
https://pubmed.ncbi.nlm.nih.gov/22404426
https://pubmed.ncbi.nlm.nih.gov/22404426